Synergistic Probiotic Blends for Enhanced Vaginal Microbiome Modulation

A next-generation probiotic system for vaginal health, featuring synergistic blends of Lactobacillus paracasei MG4272 and additional probiotic strains, which exhibit enhanced antimicrobial activity against Gardnerella vaginalis and Candida albicans.

The original patent disclosed a composition comprising a cell-free supernatant of Lactobacillus paracasei MG4272 strain, which demonstrated antifungal and antimicrobial activity. However, the original patent's composition may have limitations in terms of its efficacy, stability, and adaptability to individual vaginal microbiomes. The new inventive concept addresses these limitations by introducing synergistic probiotic blends and novel delivery systems, enabling more effective and personalized vaginal microbiome modulation.

The new inventive concept comprises a system for modulating the vaginal microbiome, featuring a synergistic blend of Lactobacillus paracasei MG4272 and at least one additional probiotic strain. This blend exhibits enhanced antimicrobial activity against Gardnerella vaginalis and Candida albicans. The system may be administered through various delivery methods, including pharmaceutical compositions, vaginal implants, and personalized diagnostic tests. The Lactobacillus paracasei MG4272 strain may be co-administered with prebiotic compounds to enhance its growth and activity in the vaginal microbiome. The inventive concept enables more effective prevention and treatment of vaginal infections, while also providing a platform for personalized vaginal microbiome modulation.

The new claims introduce a paradigm shift in vaginal microbiome modulation by combining Lactobacillus paracasei MG4272 with additional probiotic strains, creating synergistic blends with enhanced antimicrobial activity. The use of novel delivery systems, such as vaginal implants and personalized diagnostic tests, further differentiates the new inventive concept from the original patent.

Alternative embodiments of the inventive concept may include different probiotic strain combinations, varying delivery methods, and tailored formulations for specific vaginal microbiome profiles. Variations of the inventive concept may also involve the use of different prebiotic compounds, or the integration of additional therapeutic agents to enhance the system's efficacy.

The new inventive concept has significant commercial potential in the women's health and vaginal care markets, with applications in preventing and treating vaginal infections, promoting vaginal health, and supporting reproductive wellness. The market for vaginal probiotics is expected to grow significantly in the coming years, driven by increasing awareness of the importance of vaginal microbiome balance and the need for more effective and personalized treatments.